Target Price Increased on Biotech After Q2/18 Revenue Record, Beat
Source: Streetwise Reports
July 5, 2018 (Investorideas.com Newswire) A Maxim Group report explained the likely reasons behind revenue growth for the firm, which produces media used in development of cell therapies.
In a July 2, 2018 research note, analyst Jason McCarthy wrote that BioLife Solutions Inc. (BLFS:NASDAQ) reported another record quarter, Q2/18, for revenue and increased guidance again. On this news, Maxim raised its target price on Buy-rated BioLife to $18 per share from $12. The stock, which rallied on the news, is currently priced at around $16.70 per share.
BioLife's preliminary Q2/18 cell media revenue beat expectations at $5.2 million ($5.2M). The figure was up 36% quarter over quarter and 103% year over year. "Recall that each approved cell therapy drug that uses BioLife's media can potentially generate $500,000 to $2M in recurring annual revenue," noted McCarthy. Cash flow positive, the company has $14M on the balance sheet. Management increased guidance to $18.5–20M from $14.5–15.5M.
McCarthy pointed out that uptake of BioLife's cell preservation media have increased over the past year and along with it, the company's valuation. "We expect this trend could continue and valuation to continue to rise as more cell therapies advance to later stages of development and gain approval(s)." Today, BioLife has more than 2,000 customers.
The analyst proffered reasons for the expanding use of BioLife's products. One, "the cell therapy space continues to grow exponentially," he said. For example, Kolon Life Science Inc. (102940:KOSDAQ) got approval in November 2017 of its cell-mediated therapy for use in knee osteoarthritis in Korea.
As such, the number of clinical applications for BioLife's media, currently at about 300, is also rising. About a dozen of those uses are in chimeric antigen receptor T cell (CAR-T) therapies, which also are "gaining commercial traction." For instance, Kite Pharma received approval of its CAR-T Yescarta in October as a treatment for certain types of non-Hodgkin's lymphoma.
Additionally, BioLife's "media and cold chain logistics platform" better helps cells maintain viability and recover, and ultimately gets the "most efficacious, viable product to patients," McCarthy wrote. These qualities differentiate BioLife's product from others. "BioLife's media and logistic expertise (shippers) and more represent the best in the industry."
McCarthy concluded, "As cell therapy grows, so does BioLife as the tangential play."
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
Disclosures from Maxim Group, BioLife Solutions Inc., July 2, 2018
I, Jason McCarthy, Ph.D., attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.
I, Caroline Palomeque, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.
The research analyst(s) primarily responsible for the preparation of this research report have received compensation based upon various factors, including the firm's total revenues, a portion of which is generated by investment banking activities.
Maxim Group makes a market in Biolife Solutions, Inc.
Maxim Group expects to receive or intends to seek compensation for investment banking services from Biolife Solutions, Inc. in the next 3 months.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.